Showing papers by "Francois-Xavier Mahon published in 2011"
TL;DR: It is shown that poor adherence is the principal factor contributing to the loss of cytogenetic responses and treatment failure in patients on long-term therapy.
301 citations
TL;DR: It is concluded that an oncogenic signaling mediated by Lyn and Syk can bypass the need of Bcr-Abl in CML cells, and targeting these kinases may be of therapeutic value to override imatinib or nilotinib resistance in C ML.
104 citations
TL;DR: It is hypothesized that the overexpression of the TWIST-1 oncogene represents a novel key prognostic factor potentially useful for optimizing CML management in the TKI era.
54 citations
TL;DR: The updated results from the first 100 pts included in the STIM study with a longer FU are presented, confirming that all patients were sensitive to an imatinib re-challenge and 2 independent prognostic factors for prediction of molecular relapse after Imatinib cessation.
47 citations
TL;DR: Results establish, for the first time, a link between a recurrent chromosomal translocation and the development of this particular subtype of infant leukemia.
43 citations
TL;DR: Stopping TKI may be envisaged in pts with stable undetectable molecular residual disease (UMRD), as suggested by recent results from the STop IMatinib trial, and the observation that dasatinib could be safely stopped in a pt with a stable UMRD suffering from drug-induced pleural effusion.
35 citations
TL;DR: The combination of IM with a standard "3+7" regiment was well tolerated and provided a high response rate, and more than 55% of the patients achieved CHR and hematopoietic stem cell transplantation was feasible in half of the cases.
27 citations
TL;DR: A multivariate analysis adjusted on progression-free survival (PFS) performed, did not identify any significant parameter including age, gender, Sokal and Hasford scores, ACA, type of transcript, interval between diagnosis and TKI start.
9 citations
TL;DR: Mahon et al. as discussed by the authors reported the results of imatinib discontinuation in CML pts in complete molecular response (CMR) for more than 2 years under IM therapy (STIM study).
9 citations
TL;DR: In this paper, the authors investigated whether patients on long-term imatinib would be more likely to achieve undetectable BCR-ABL levels if they switched to nilotinib, allowing for participation in potential cessation studies in the future.
7 citations
TL;DR: The variation of expression of α-defensin 1-3 and α- defensin 4 in peripheral blood is associated with imatinib resistance and may reflect an adequate immune control of the disease.
Abstract: Objective: Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukaemia. Despite a remarkable effectiveness, treatment failure cases have been reported in 20 percent of CML patients. The identification of biomarkers which can predict the response to imatinib is our point of interest.
TL;DR: A single centre retrospective analysis of de-novo AML with a cytogenetically intermediate-risk profile treated at 1st CR with a RIC ASCT or conventional consolidation chemotherapy in the absence of a suitable donor is compared.
TL;DR: Results demonstrate that CML-iPSC survival do not depend on BCR-ABL (oncogene independence) and study the mechanism of TKI resistance of the stem cells.
TL;DR: The SPIRIT phase III randomized multicenter open-label prospective trial was designed to compare 4-arm, imatinib 400 mg versus IMatinib 600 mg versus imatiniber 400 mg + cytarabine at a dose of 20 mg/m2/day in cycles of 28 days, versus iminib 400mg + PegIFN at an initial dose of 90 μg/week as discussed by the authors.